News & Updates

Show Multimedia Only

Remnant cholesterol predicts NAFLD development

23 Nov 2023

Serum levels of remnant cholesterol may be used to assess an individual’s susceptibility to developing nonalcoholic fatty liver disease (NAFLD), independent of traditional lipid profiles, suggests a recent study.

Remnant cholesterol predicts NAFLD development

23 Nov 2023

HBV vaccine improves survival of patients with chronic liver disease

22 Nov 2023 by

Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.

HBV vaccine improves survival of patients with chronic liver disease

22 Nov 2023

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

21 Nov 2023 by

Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) rarely results in severe drug-induced liver injury among adults with cystic fibrosis, as shown in a study presented at AASLD 2023. Moreover, serum markers of fibrosis have increased but remain within normal range.

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

21 Nov 2023

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023 by

A combination regimen comprising bulevirtide 10 mg (BLV10) and pegylated interferon alpha-2a (PegIFNα) improved multiple liver parameters in patients with chronic hepatitis delta (CHD), findings from the phase IIb MYR204 study have shown.

Bulevirtide-PegIFNα combo yields benefits for CHD patients

21 Nov 2023

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023 by

An 8-week course is as good as a 12-week course of tenofovir alafenamide fumarate (TAF) therapy in terms of preventing the transmission of hepatitis B virus (HBV) infection from mothers to infants, as reported in a study.

8-week TAF course enough to prevent mother–child HBV transmission

20 Nov 2023

Machine perfusion delivers positive outcomes for liver transplantation

18 Nov 2023

Machine perfusion techniques are effective and appear to be better than static cold storage (SCS) in patients who underwent liver transplantation, suggest the results of a meta-analysis.

Machine perfusion delivers positive outcomes for liver transplantation

18 Nov 2023

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Treatment with antiviral therapy is beneficial and generally tolerated in children with chronic hepatitis B virus (HBV) infection in the immune-tolerant stage, according to the results of a systematic review and meta-analysis.

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

28 Oct 2023

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 by

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

23 Oct 2023 by

Waitlisted registrants for liver transplantation (LT) who have nonalcoholic steatohepatitis (NASH) cirrhosis have a lower chance to receive a new organ and greater risk of waitlist mortality at 90 days and 1 year than patients with non-NASH cirrhosis, suggest the results of a Singapore study.

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

23 Oct 2023

News & Updates

Showing Hepatology articles

Showing

Specialty:

Remnant cholesterol predicts NAFLD development

Remnant cholesterol predicts NAFLD development

HBV vaccine improves survival of patients with chronic liver disease

HBV vaccine improves survival of patients with chronic liver disease

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?

Bulevirtide-PegIFNα combo yields benefits for CHD patients

Bulevirtide-PegIFNα combo yields benefits for CHD patients

8-week TAF course enough to prevent mother–child HBV transmission

8-week TAF course enough to prevent mother–child HBV transmission

Machine perfusion delivers positive outcomes for liver transplantation

Machine perfusion delivers positive outcomes for liver transplantation

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Antiviral therapy safe, effective in children with immune-tolerant HBV infection

Canagliflozin holds promise against MAFLD in T2D patients

Canagliflozin holds promise against MAFLD in T2D patients

Liver transplant candidates with NASH cirrhosis less likely to receive new organ

Liver transplant candidates with NASH cirrhosis less likely to receive new organ